 Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) |
We are committed to helping your patients breathe easier in the hospital, at home and on the go. For many people, breathing is a struggle. We are focused on supporting you and your care team with innovative products that deliver effective, proven respiratory care, whenever and wherever it is needed. Whether therapy is necessary for short-term, post-operative recovery or for on-going support of symptoms of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic conditions, we are focused on helping you live your best life with fewer restrictions.
(Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) |
